Back to Posters

Germline mutation likelihood in breast cancer patients: Navigating the nuances of multi-gene panel testing

Session:
#641
Date:
Thursday, Mar 8, 2018 6:00pm – 8:00pm
Conference:
Miami Breast Cancer Conference 2018
Authors:
Carrie Horton, Holly Laduca, Kelly Fulk, Lily Hoang
  • Positive rates increased in individuals meeting various NCCN BRCA1/2 testing criteria as panel size increased, with the exception of the TNBC criterion and the family history of male BC criterion.
  • Our findings that mutation likelihood based on clinical presentation differ by panel highlight the need to tailor risk assessment for MGPT rather than relying on tools designed for single gene testing.
  • Continued exploration of panel and phenotype-specific detection rates will improve pre-test risk counseling in the MGPT setting.
Abstract